Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medeor Therapeutics Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units. SKELDING, ZACHARY S is the busiest examiner for the portfolio, with 1 busiest examiner pending matter under review. The presence of 2 pending office actions in 2 distinct art units indicates that the company's innovations cover different technical categories within the pharmaceutical sector.
With 2 distinct examiners involved, the prosecution strategy must account for the specific preferences of each individual. SKELDING, ZACHARY S manages 1 busiest examiner pending case, while the other pending action is handled by a different examiner in a separate art unit. This distribution across 2 distinct art units suggests a technical portfolio that requires specialized knowledge for each of the 2 pending office actions. Practitioners must coordinate their responses to ensure that the 1 busiest examiner pending matter and the other active case remain consistent. The 2 pending office actions represent the full extent of the company's current examination activity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18367728 | METHODS OF PRODUCING MIXED CHIMERISM AFTER A SOLID ORGAN TRANSPLANT | LEE, YIE CHIA | 6d |
| 18378963 | CELLULAR COMPOSITIONS DERIVED FROM DECEASED DONORS TO PROMOTE GRAFT TOLERANCE AND MANUFACTURE AND USES THEREOF | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18378963 | CELLULAR COMPOSITIONS DERIVED FROM DECEASED DONORS TO PROMOTE GRAFT TOLERANCE AND MANUFACTURE AND USES THEREOF | SKELDING, ZACHARY S | 1644 | §103Other | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18367728 | METHODS OF PRODUCING MIXED CHIMERISM AFTER A SOLID ORGAN TRANSPLANT | LEE, YIE CHIA | 1642 | §103Other | Non-Final OA | 6d | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial